MedTrace Logo

Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study

NCT05372263 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2025-12-04

No results posted yet for this study

Summary

Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.

Conditions

  • Pulmonary Hypertension

Sponsors & Collaborators

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Lu Hua, M.D · Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility

Min Age
3 Months
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372263 on ClinicalTrials.gov